Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
Methodology to determine the immune profile. Fluorescent cytometric measurements provide relative quantities of immune system cells in terms of the depicted known percentages. CTL: Cytotoxic T-cells; NK: natural killer cells; PD1: programmed death receptor 1; Th: T-helper cells; Treg: regulatory T-cells.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Canonical correlation analysis of immune profiles versus overall survival (OS). The immune profile is composed of the different FACS-derived quantities (features). Diagrams for four subgroups are shown. A: Vaccination during temozolomide maintenance chemotherapy (TMZm), no residual tumor volume after resection; B: vaccination after TMZm, no residual tumor volume after resection; C: vaccination during TMZm, non-zero residual tumor volume after resection; D: vaccination after TMZm, non-zero residual tumor volume after resection. Each diagram depicts the strong correlation between Q (x-axis), where Q is the sum of quantities of the form: coefficient × [feature – mean of feature in the specific subgroup], and OS (y-axis) expressed as the quantity OS being the individual OS in months minus the mean OS, i.e. mean OS for the specific subgroup.